Mereo BioPharma focuses on optimizing patient access as it builds out its rare disease commerctial infrastructure
February 26, 2018Mereo BioPharma has decided to put focus on optimizing its patient access and commercialization strategies, as it builds out its rare disease commercial infrastructure. In that sense, the company has appointed Wills Hughes-Wilson as Head of Patient Access and Commercial Planning, in a part time role.
Dr. Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma said: “Ms. Hughes-Wilson brings in-depth market access and product launch expertise as well as a proven ability to develop and lead commercial planning efforts globally. With extensive experience in the rare and orphan disease areas, Ms. Hughes-Wilson will be instrumental as we advance our portfolio of rare product candidates through late-stage clinical development and towards commercialization. We are very pleased to welcome her and believe she will be a strong complement to our existing leadership team at Mereo.”
Most recently, Ms. Hughes-Wilson served on the Executive Leadership Team as Chief Patient Access Officer and Senior Vice President Access & External Affairs at Swedish Orphan Biovitrum (Sobi), an international specialty healthcare company dedicated to rare diseases, and before that she served as Vice President of Health and Market Access Policy at Genzyme Corporation (now part of Sanofi).
Commenting the new role in a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, Hughes-Wilson said: “Mereo’s robust portfolio of product candidates, including BPS-804 for the treatment of osteogenesis imperfecta and AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency, has the potential to address significant unmet medical needs in rare diseases. I look forward to applying my experience to help the Company continue its journey to develop these therapies and, if approved, make them commercially available to patients and healthcare systems in a timely and sustainable manner.”
Image: Mereo BioPharma CEO, Dr. Denise Scots-Knight, with the logo of the company
